Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

已完结 10 由达姆发布于 2026/8/11 9:20:14

DOI:10.1016/S1474-4422(24)00328-4
作者：Xavier Montalban,?Patrick Vermersch,?Douglas L Arnold,?Amit Bar-Or,?Bruce A C Cree,?Anne H Cross,?Eva Kubala Havrdova,?Ludwig Kappos,?Olaf Stuve,?Heinz Wiendl,?Jerry S Wolinsky,?Frank Dahlke,?Claire L
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare

应助信息

17小时前

xiechao

a3f220bb952311f190b234735aa3bc31.pdf 已采纳

17小时前

Book学术机器人

2026/8/11 9:20:14 未找到该文献，机器人已退出，请等待人工下载

2026/8/11 9:20:14 Book学术AI机器人收到请求，开始寻找文献

2026/8/11 9:20:14 已向机器人发送请求

17小时前

达姆发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Effect of Co3+ Doping on Crystal Structure and Electrochemical Properties of Spinel LiMn2O4 Cathode Material